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Background: Artemisinin resistance described as increased parasite clearance time (PCT) is rare in Africa.
More sensitive methods such as qPCR might better characterize the clearance phenotype in sub-Saharan
Africa.
Methods: PCT is explored in Mali using light microscopy and qPCR after artesunate for uncomplicated
malaria. In two villages, patients were followed for 28 days. Blood smears and spots were collected
respectively for microscopy and qPCR. Parasitemia slope half-life was calculated after microscopy. Patient
residual parasitemia were measured by qPCR.
Results: Uncorrected adequate clinical and parasitological responses (ACPR) observed in Faladje and
Bougoula-Hameau were 78% and 92%, respectively (p = 0.01). This reached 100% for both after molecular
correction.
Proportions of 24H microscopy positive patients in Faladje and Bougoula-Hameau were 97.2% and 72%,
respectively (p < 0.0001).
Slope half-life was 2.8 h in Faladje vs 2H in Bougoula-Hameau (p < 0.001) and
Proportions of 72H patients with residual parasitemiawere 68.5% and40% in Faladje andBougoula-Hameau,
respectively (p = 0.003). The mean residual parasitemia was 2.9 in Faladje vs. 0.008 in Bougoula-Hameau
(p = 0.002).
Although artesunate is efficacious in Mali, the longer parasite clearance time with submicroscopic
parasitemia observed may represent early signs of developing P. falciparum resistance to artemisinins.
© 2020 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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Malaria is still a devastating disease in endemic regions despite
major efforts for its control and elimination. Artemisinin-based
Combination Therapies (ACT) are first line treatment for malaria
case management (WHO, 2015). Combining fast acting artemisi-
nin- which drastically reduces the parasite biomass- with a long-
lasting partner drug that clears the remaining parasitemia would
protect both drugs from parasite resistance (Davis et al., 2005).
First decreased efficacy of Plasmodium falciparum to artemi-
sinins observed in vivo was reported in South-east Asia and defined* Corresponding author.
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1201-9712/© 2020 The Authors. Published by Elsevier Ltd on behalf of International So
(http://creativecommons.org/licenses/by/4.0/).as a delay in clearance of parasite as measured by light microscopy
(Noedl et al., 2008; Dondorp et al., 2009; WWARN, 2010; Flegg
et al., 2013). Treatment failures were increasingly observed during
clinical trials in the Greater Mekong regions (Dondorp et al., 2009).
Resistance to artemisinin based combination therapies (ACTs) or to
artemisinin derivatives in monotherapy were observed in several
places in Asia (Cheeseman et al., 2012; Phyo et al., 2012; Ashley
et al., 2014; Takala-Harrison et al., 2014; Imwong et al., 2017). The
short half-life of artemisinins in patients (Navaratnam et al., 2000)
led to a number of modifications on the standard P. falciparum
drug resistance assessment methods to allow a proper monitoring
of emerging resistance to these new compounds. Different in vitro,
in vivo and molecular methods were thus adapted to artemisinins
efficacy studies (Witkowski and Amaratunga, 2015; Stepniewska
et al., 2010a; Flegg et al., 2013; Ariey et al., 2014). Several pointciety for Infectious Diseases. This is an open access article under the CC BY license
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to the parasite clearance phenotype (Ariey et al., 2014).
Despite several studies on artemisinins efficacy in Africa, delay
in parasite clearance time were rarely found (Borrmann et al., 2011;
Ashley et al., 2014). Mutations on PfK13 propeller were observed in
very rare cases, in low frequency. In addition, the PfK13 mutations
found in sub-Saharan Africa were mostly different from the ones
associated with delay in parasite clearance time (PCT) in SE-Asia
(Kamau et al., 2017; Maiga et al., 2012; Ouattara et al., 2015; Taylor
et al., 2015; Ménard et al., 2016a). A few studies in eastern Africa
found Asian mutations of PfK13 propeller resistance mutations but
those mutations were not associated with prolonged parasite
clearance (Borrmann et al., 2011; Tacoli et al., 2016).
Other studies either in Africa or even in Asia found delayed
parasite clearance without PfK13 propeller mutations (Muwanguzi
et al., 2016; Neher, 2016 and MalariaGEN Plasmodium falciparum
Community Project 2016; Mukherjee et al., 2017). Many factors
related to both parasite genetic background and host immunity
could explain differences observed in parasite clearance pheno-
types between sub-Saharan Africa and south-east Asia (Djimde
et al., 2003; Borrmann et al., 2011). In the contrary to the Asian
parasites, little to no data were available for African field parasite
sensitivity to ACT component drugs prior to their adoption for
malaria treatment. Given the significant morbidity and mortality
still associated with malaria in sub-Saharan Africa (Organization,
2018), efficient monitoring for efficacy of ACTs as well as their
artemisinin's component is critical in Africa for malaria control and
elimination strategies. This surveillance became even more critical
for artesunate since it is now the first line therapy for the
management of severe and complicated malaria cases in males and
non-pregnant females. More sensitive tools may be needed to
better characterize the phenotype of parasites and for early
detection of P. falciparum resistance to artemisinin in Africa.
Studies using qPCR to follow parasites clearance after ACTs found
that, in addition to replicating parasite density derived from
microscopy, this molecular method was able to detect submicro-
scopic parasitemia and give a clearer phenotype for parasite
clearance time during field clinical trials in Africa (Beshir et al.,
2010).
This present study compared the parasite clearance time after
artesunate monotherapy treatment of uncomplicated malaria
cases in two different areas of Mali, using both light microscopy
and qPCR.
2. Materials and Methods
2.1. Study design and participants
Between October 2015 and March 2016, a prospective
artesunate monotherapy study was conducted in Faladje and
Bougoula-Hameau, two malaria endemic villages in Mali. Both
villages have seasonal malaria transmission, are located in
southern Mali but 400 kilometers apart.
Faladje is located at 80 kilometers West of Bamako (the capital
city of Mali). Malaria transmission in Faladje is intense between
July and October (Kayentao et al., 2009). Bougoula-Hameau is
situated at 380 kilometers South of Bamako with rainy seasons
lasting 6 months from May to October, and intense malaria
transmission between July and November (Bouvier et al., 1997).
The trial enrolled patients of 6 months of age and older in both
Faladje and Bougoula-Hameau.
The main inclusion criteria were an axillary temperature 
37 C or a reported history of fever in the previous 24 hours, a blood
smear parasitemia between 2000 and 200,000 P. falciparum
asexual forms per microliter, hemoglobin levels greater than
8.0 g/dl and no declared allergy to artemisinins. Volunteers withother acute illnesses or those with severe/complicated malaria
were not included in this study. Participants were included after
written informed consent, assent or parental consent for minors
was obtained. A treatment course of 7 days of artesunate was
administered at a first single dose of 4 mg/kg at inclusion day
followed by a daily single dose of 2 mg/kg for the remaining of the
treatment course. Patients were actively followed for 28 days
according to modified standard protocols (Djimdé et al., 2008).
Patients were hospitalized from inclusion to the resolution of
malaria symptoms sustained by three consecutive negatives blood
smears.
For the light microscopy clearance assessment, thick and thin
blood smears were realized from finger pricks every 8 hours to also
capture potential parasite burst from non-synchronic infections.
This collection started from inclusion until three consecutively
negative slides were obtained, as per the Worldwide Antimalarial
Resistance Network (WWARN) adapted protocols (Flegg et al.,
2013). After three consecutively negative slides, additional finger
pricks were performed on days 7, 14, 21, 28 and/or on unscheduled
days of clinical visit. Giemsa staining and microscopy were
performed to measure asexual and sexual parasite densities.
Parasitemia was assessed by counting the number of asexual forms
per 200 leucocytes according to described protocols (WHO, 2013).
Gametocytes density was estimated on 1000 leucocytes as
described elsewhere (Von Seidlein et al., 2001). Patients were
followed-up for 28 days with visits at days 7, 14, 21, 28 and any
unscheduled days if the volunteer needed medical attention.
Microscopy slide-reading was performed by two experienced
readers, with discrepancies resolved by a third one.
Dried blood spots (DBS) were obtained at inclusion and every
8 hours until three consecutive negative slides were obtained, then
at days 7, 14, 21, 28 and/or at unscheduled days of clinical visit.
PCR was performed to discriminate reinfections from recru-
descent infections by using the molecular markers of parasite
polymorphism msp1, msp2 and Ca1, as described elsewhere
(Snounou and Beck, 1998; Mugittu et al., 2006).
Treatment outcomes were assessed according to modified
WHO protocol and classified as Early Clinical Failure (ECF), Late
Clinical Failure (LCF), Late Parasitological Failure (LPF) and
Adequate Clinical and Parasitological Response (ACPR) (WHO,
2013). Treatment failures were managed with ACTs or quinine
intra-venously in 10% glucose followed by oral treatment as the
patient status evolved. Cases that could not be handled in the local
health center were referred to the nearest Hospital.
2.2. Parasite clearance time estimation
Light microscopy: the well-established parasite clearance time
parameter was determined as the time from the first positive blood
slide at inclusion to the time of the first negative slide followed by
two consecutives negative slides. The WWARN parasite clearance
estimator (PCE) was used to calculate parasite clearance slope half-
life and the clearance rate constant (WWARN, 2010). Other
parameters such as the proportion of patients having cleared
90% to 100% of their parasitemia by day 1 and the time to clear 50%,
90% or 100% of the day 0 parasitemia were also considered in this
study.
qPCR: Samples were processed at the Malaria Research and
Training Center in Bamako, Mali using a qPCR cycler (Light Cycler
480, Roche1, Mannheim, Germany). DNA was extracted from DBS
collected prior to treatment, and at 24, 48 and 72 hours afterwards
as previously described (Walsh et al., 1991). Parasitemia reduction
was assessed by applying a relative quantification in the same
sample of a parasite gene coding for the Plasmodium tRNA
methionine (pgMET) and a human gene coding for the human
β tubulin (HumTuBB). From the initial parasitemia, Parasite
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48H and 72H) for each patient (Livak and Schmittgen, 2001; Beshir
et al., 2010). Patients were considered as cleared when they
reduced their initial parasitemia to a rate of 1/10,000, they were
considered as having residual parasitemia when this rate was
not met.
For each time point, a mean was calculated on patient's residual
parasitemia per village.
2.3. Molecular markers of drug resistance
Several molecular markers for drug resistance were analyzed
for their polymorphism in the two study sites. Day 0 dried blood
spots collected on patients before drug administration were sent to
whole genome sequencing at Wellcome Sanger Institute (Well-
come Genome Campus, Hinxton, UK). Polymorphisms for Pfmdr1,
Pf K13, Pfdhfr and Pfdhps as well as Pfmdr2, arps10, and ferredoxin
(parasite genetic background, PGB (Miotto et al., 2015)) Pfcrt K76 T
genotype was analyzed by nested PCR as previously described
(Djimde et al., 2001). A baseline prevalence for mutant parasites
was determined for selected SNPs on those different genes for each
study site.
2.4. Data analysis
Data was included in the final analysis when the patient
received the full dose of treatment, had not received another
antimalarial treatment and attended all follow up visits. The
sample size was calculated based on the in vivo clinical and
parasitological failure rate around 17% on Day 28 using artemether-
lumefantrine as the reference drugs in Mali (Sagara et al., 2016).
Assuming a random error estimate at 5%, the α-level of test at 5%
and the power (1-β) of 80%, the number of evaluable volunteers
necessary for the study was 216 for both sites.
Proportions, medians and means were measured by descriptive
statistics and compared by the χ2 test, the student's t test or the
Wilcoxon-Mann Whitney test as appropriate. The main parameters
affecting parasite clearance such as patient age and the initialFig. 1. Studyparasitemia were included in the model as confounding factors as
well as sex, hemoglobin levels, gametocyte density and fever at
enrolment. Data were entered in excel 2011 and STATA version 11.2
for statistical analysis. The genotyping data for each molecular
marker was extracted from the MalariaGEN genetic report card
based for these locations. Missing data were removed and the
frequency of variations in each molecular marker was calculated
using the dplyr package implemented in R [Hadley Wickham,
Romain François, Lionel Henry and Kirill Müller (2019). R package
version 0.8.3.]
The study protocol was reviewed and approved by the Ethics
Committee of the Faculty of Pharmacy and the Faculty of Medicine
and odonto-stomatology, University of Sciences Technics,
Technologies of Bamako, Mali.
3. Results
3.1. Clinical/parasitological outcomes
Overall 221 volunteers were included in this study, 121 from
Faladje and 100 from Bougoula-Hameau. One exclusion case for
persistent vomiting after drug administration was observed in
Faladje. No other losses to follow up happened for the two study
sites (Fig. 1). At enrolment, the two study populations were
comparable for sex ratio, median asexual parasitemia, mean
hemoglobin, proportions of anemia, fever and gametocyte carriage
as well as mean gametocyte density (Table 1).
There were 2 LCF and 24 LPF cases (78.3% ACPR) registered for
Faladje versus 8 LPF (92% ACPR) for Bougoula-Hameau (p = 0.01).
After PCR correction, all recurrent infections were new infections,
bringing the artesunate PCR corrected cure rate to 100% in both
villages.
3.2. Parasite clearance assessed by light microscopy
At eight hours after treatment initiation, only 1.7% of Faladje
patients had an increase in the baseline parasitemia while in
Bougoula-Hameau 39% of patients had an increase in the baseline profile.
Table 1
Demographic characteristics at enrolment
Parameters Faladje Bougoula-Hameau p value
Age, median in year (IQR) 8.5 (5.5-11.2) 9 (6.8-11.7) 0.2
Male sexe n (%) 55 (45.8%) 53 (53%) 0.4
Pf * parasitemia/ul, median (IQR) 25,680 [14,540-53,720] 29,140 [19,080-53,820] 0.5
Pf* Gametocyte/ul, mean (SD) 40 [24] 71 [60.8] 0.4
Pf* Gametocyte carriers, n (%) 3 (2.5%) 8 (8%) 0.06
Hemoglobin, mean (SD) 11.01 [1.6] 11.1 [1.5] 1
Anemia, n (%) 60 (50%) 44 (44%) 0.5
Fever, n (%) 57 (47.5%) 56 (56%) 0.3
* : Plasmodium falciparum
Fig. 2. Distribution of H8 parasitemia around the initial H0 parasitemia value of 1.
Table 2
Parasite clearance parameters using light microscopy
Faladje Bougoula-Hameau p value
Proportion of patients with cleared parasitemia 24 h after treatment 3 (2,5%) 28 (28%) <0.0001
Time in hour to clear 50% of the parasitemia, median (IQR) 6,7 [4,6-10,6] 4,6 [3,7-5,5] <0.0001
Time in hour to clear 90% of the parasitemia, median (IQR) 11,8 [8,9-15] 10,6 [9-12,2] 0.04
Total clearance time, median (in hour) 40 32 P < 0,0001
Fig. 3. P. falciparum clearance half-life distribution post-artesunate monotherapy in
Faladje and Bougoula-hameau, Mali.
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cases by a rapid decrease of the general parasite density between
16 to 24 hours after treatment initiation. At 24 hours following
artesunate treatment, 97.5% of Faladje patients had detectable
parasitemia against 72% in Bougoula-Hameau (P < 0.0001). At
72 hours post-treatment, patients from neither study sites had a
microscopically detectable parasitemia. The median times to
clear 90% of the initial parasitemia was 11.8 hours in Faladje vs
10.6 hours for Bougoula-Hameau (P = 0.04). The median time to
clear all parasitemia was significantly longer in Faladje with
40 hours compared to Bougoula-Hameau with 32 hours
(P < 0.0001) (Table 2).
Using the WWARN PCE tool, the parasite clearance slope half-
life was significantly longer in Faladje with a median of 2.8 hours
than in Bougoula-Hameau with 2 hours (P < 0.0001) (Fig. 3). There
was a correlation between parasite clearance and both age
(P = 0.02) and initial parasitemia (P = 0.03) in Bougoula-Hameau.
This was not observed in Faladje.
3.3. Parasite clearance assessed by qPCR
Complete qPCR results were obtained for 104 (54 for Faladje
and 50 for Bougoula-Hameau) out of 111 analyzed samples.
For the first 24 and 48 hours following artesunate treatment,
the proportions of patients with residual parasitemia was
comparable for the two study sites (Fig. 4). At 72 hours the
proportion of patients with residual parasitemia was 68.5% in
Faladje and 40% in Bougoula-Hameau (P = 0.003). The mean
residual parasitemia of all patients at 72 hours was 2.9 and 0.08
for Faladje and Bougoula-Hameau, respectively (P = 0.001)3.4. Molecular markers of drug resistance
Only one non-synonymous PfK13 mutation was found in
Bougoula-Hameau (A578S) (N = 98), while no such mutation was
found in Faladje (N = 118). The prevalence of Pfcrt K76 T, Pfmdr1
N86Y, Pfdhfr-Pfdhps quadruple mutations in Faladje and Bougoula-
Hameau were comparable (Table 3). One Pfdhfr-Pfdhps quintuple
mutant was observed in Bougoula-Hameau only. There was no
difference in the prevalence of PGB haplotypes between the two
sites (Table 3).
Fig. 4. Proportion of patient with residual parasitemia measured by qPCR in Faladje
and Bougoula-hameau. At 24 hours and 48 hours the two villages were comparable
with, Faladje presenting 92,6% and Bougoula-hameau 94% (p = 0.7) at 24 hours and
at 48 hours Faladje had 79,6% and Bougoula-hameau 66% (p = 0.1).
Proportions at 72 hours were different with 68.5% in Faladje and 40% in Bougoula-
hameau (p = 0.003) *
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Following artesunate monotherapy for uncomplicated falcipa-
rum malaria, parasite clearance time (PCT) was significantly longer
in Faladje than in Bougoula-Hameau, using both light microscopy
and qPCR. Although, the nearly 3-hour slope half-life of para-
sitemia clearance of Faladje did not reach the current 5-hour
threshold for artemisinin resistance described in SEA (Dondorp
et al., 2009), this observation merits careful consideration. The PCT
found in Bougoula-Hameau is similar to PCTs reported ten years
earlier in the same site (Maiga et al., 2012) as well as in Kenieroba,
another village of Mali (Lopera-Mesa et al., 2013). It is also
comparable to the one observed in a similar study conducted in DR
Congo (Ashley et al., 2014). As with light microscopy qPCR showed
significantly slower PCT in Faladje than in Bougoula-Hameau.
Furthermore, there were significantly more patients with qPCR
detectable parasitemia 3 days after treatment initiation in Faladje
than Bougoula-Hameau. Residual parasitemia detected by qPCR
was described as being associated with malaria transmission and
with the development of drug resistance (Beshir et al., 2013). The
rate of 72 hour - parasitological failure by qPCR varied between 40%
and 68% while the rate of 72 hour - parasitological failure by
microscopy was 0% in both villages, indicating that qPCR would be
a better tool for the early detection of artemisinin resistance in
these settings.
A number of hosts, parasite and environmental factors might
affect parasite elimination from the bloodstream. Differences inTable 3
Molecular markers of drug resistance in the two study sites
Genes Antimalarial Amino Ac
PfK13 artemisinin any mutat
in BTB/PO
Pfdhfr-Triple-mutation pyrimethamine 51,59,108 
Pfdhfr-Pfdhps quadruple mutation Sulfadoxine-pyrimethamine 51,59,108, 
Pfdhfr-Pfdhps quintuple mutation Sulfadoxine-pyrimethamine 51,59,108, 
Pfmdr1 chloroquine, amodiaquine,
lumefantrine, mefloquine
86 
Pfcrt chloroquine 76 
PGB (ART-R genetic background),
arps10, ferredoxin, Pfcrt, Pfmdr2
artemisinin arps10-12
Pfcrt-326,malaria transmission levels could impact the PCT (Stepniewska
et al., 2010b). In our two study sites malaria transmission was
shown to be comparable (Bouvier et al., 1997; Kayentao et al.,
2009). Therefore, the difference in PCT between these two villages
are probably not due to differences in transmission. Because both
Faladje and Bougoula-Hameau are regularly used as antimalarial
drug testing sites, this could have an impact on parasites
susceptibility. However, the sites are being used at similar
frequency for these studies and solely by our research team.
Host immunity is known to significantly contribute to parasite
clearance (Djimde et al., 2003; Ataide et al., 2017). Age was
suggested to be correlated with host immunity (Djimde et al.,
2003; Lopera-Mesa et al., 2013). Because the available data suggest
that transmission and age distributions are similar between the
two sites, it is reasonable to expect similar overall levels of human
host immunity in the two villages. Furthermore, a recent study
indicated that prevalence of anti P. falciparum MSP1-42 and P.
falciparum AMA-1 antibodies were similar between the two areas
where the respective villages are located (Rogier et al., 2017). More
studies will be required to clarify the potential role of host
immunity in the observed differences in PCT. Indeed the 5-hour
slope half-life threshold that was shown to correlate with
artemisinin decreased efficacy in South-East Asia (Ashley et al.,
2014) may not hold in sub-Saharan Africa that is still presenting
with the highest transmission intensity (World Health Organiza-
tion, 2018).
Ethnic differences have been shown to affect susceptibility to
malaria. Indeed, Fulani are less susceptible to malaria than
sympatric Mossi and Dogon ethnic groups in Burkina Faso and
Mali, respectively (Modiano et al., 1999; Dolo et al., 2012).
However, more than 95% of residents of Faladje and Bougoula-
Hameau share the same last name, which indicates that they are
most likely of similar ethnic background (our unpublished
observations).
Only PfK13 A578S mutation was found in one infection in our
dataset. This mutation was observed in previous studies in Mali
(Ouattara et al., 2015) and in other African countries (Kamau et al.;
Ashley et al., 2014; Ménard et al., 2016b). However, PfK13 A578S
appears not to be involved with artemisinin resistance (Kamau
et al.; Muwanguzi et al., 2016). We note that an increasing number
of studies describe artemisinins resistance in the absence of PfK13
mutations (Madamet et al., 2017; Ocan et al., 2018). This highlights
the possibility for Plasmodium parasites to evolve other resistance
mechanisms independently or in addition to PfK13 gene (Kheang
et al., 2017; Mukherjee et al., 2017).
A longer PCT could have been attributable to parasite genetic
background of resistance (Miotto et al., 2015). Indeed the village of
Faladje had 45% of in vivo chloroquine resistance, the highest rate
ever documented in Mali (Sangho et al., 2004) wile in the sameFaladje Bougoula-
Hameau
id Positions Wild Type
Haplotype
Mutants
%(N)
p
ion seen
Z
0 (120) 1 (100) 0.2
NCS 83.7(140) 79.6(166) 0.3614
480 NCS-A 52.6(140) 52(166) 0.9
480, 540 NCS-AK 0 (140) 0.6 (166) 0.3
N 40(118) 38.8(163) 0.8
K 30(110) 23.7(71) 0.3
7; ferredoxin-193;
 356; Pfmdr2-484
VDNIT 32.6(126) 29.6(151) 0.5
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unpublished data). Nevertheless, prevalence of current molecular
markers of antimalarial drug resistance was comparable for the
two villages (Table 3). In addition, the genetic background
associated to artemisinin resistance is similar for both sites.
Therefore, the known genetic background of drug resistance
does not explain the PCT differences observed in Faladje and
Bougoula-Hameau.
Despite these differences observed in clearance time in the two
study areas, artesunate monotherapy showed 100% corrected ACPR
and no patients had detectable parasitemia by light microscopy
72 hours after treatment, indicating high clinical efficacy of this
drug in both villages during this study period.
While less than 2% of patients had a rise in parasitemia eight
hours after treatment in Faladje, two out of every five patients had
a rise in parasitemia at the same time point. This initial rise of
parasitemia shortly after artemisinin treatment, which could be
related to the presence of non-synchronous parasite populations in
patients had been described (Silachamroon et al., 2001; Maiga
et al., 2012). The increased parasitemia observed at 8H after
treatment might be due to new merozoites from newly ruptured
schizonts (Saralamba et al., 2011). The phenomenon could
also reflect multiplicity of infection with different clones being
at different developmental stages. Other parasite factors such as
parasitemia or host factors such as immunity could also be
involved in lack of synchronicity of P.falciparum infection in people
(White, 2017). The mechanisms involved in the observed sharp
difference between the two villages in terms of rise of
initial parasitemia after artesunate treatment requires further
investigations.
Slower parasitemia clearance after artesunate monotherapy in
a village known for higher chloroquine-resistance could be early
signs of diminished response to artemisinins in Mali. Bearing in
mind the facts that the 5-hour slope half-life threshold for
artemisinin resistance/tolerance was initially established in south-
East Asia and that immunity and other host factors may mask
increases in PCT in higher malaria transmission settings, more
sensitive tools such as qPCR may be better indicated for
the monitoring of the emergence of artemisinin resistance in
sub-Saharan Africa.
Financial support
Field studies were supported by a Wellcome Sanger Interna-
tional Fellow to AAD. AAD is currently supported through the
DELTAS Africa Initiative, (DELGEME grant 107740/Z/15/Z). Malaria
Research and Capacity Development (MARCAD), a DELTAS Program
[DEL-15-010] supported Aminatou Kone through a Post-doctoral
fellowship. The Developing Excellence in Leadership and Genetics
Training for Malaria Elimination in sub-Saharan Africa (DELGEME)
a DELTAS Program [DEL-15-002] supported Aoua Coulibaly for a
PhD fellowship. The DELTAS Africa Initiative is an independent
funding scheme of the African Academy of Sciences (AAS)’s
Alliance for Accelerating Excellence in Science in Africa (AESA) and
supported by the New Partnership for Africa's Development
Planning and Coordinating Agency (NEPAD Agency) with funding
from the Wellcome Trust [grant 107741/A/15/Z] and the UK
government. The views expressed in this publication are those of
the author(s) and not necessarily those of AAS, NEPAD Agency,
Wellcome Trust or the UK government.
A.K received support from the World Academia of Sciences
(TWAS) for providing financial support through the grant number
Ref.: 17-346 RG/BIO/AF/AC_I–FR3240297741.
Corresponding author: Professor Abdoulaye A. Djimde,
adjimde@icermali.org, Malaria Research and Training Center,Faculty of Pharmacy, University of Science, Techniques and
Technology, Bamako, Mali
Declaration of Conflict of interest
Pr. Djimde has nothing to disclose.
Acknowledgments
Authors of this paper wish to address a special acknowledgment
to all the study volunteers from Faladje and Bougoula-Hameau, the
two villages administrative and health centers authorities and
the village's community heads for their collaborative support. We
thank Dr. Victoria Trinies and Prof. Seydou Doumbia for kindly
sharing the raw data of their study on malaria immunity in Mali
(Rogier et al., 2017)
References
Ariey F, Witkowski B, Amaratunga C, Beghain J, Langlois A-C, Khim N, et al. A
molecular marker of artemisinin-resistant Plasmodium falciparum malaria.
Nature [Internet]. 2014;505(7481)50–5 Available from: http://www.ncbi.nlm.
nih.gov/pubmed/24352242%0Ahttp://www.pubmedcentral.nih.gov/articleren-
der.fcgi?artid=PMC5007947.
Ashley EA, Dhorda M, Fairhurst RM, Amaratunga C, Lim P, Suon S, et al. Spread of
artemisinin resistance in Plasmodium falciparum malaria. NEnglJMed.
2014;371:411–23 (1533-4406 (Electronic)).
Ataide R, Ashley EA, Powell R, Chan J-A, Malloy MJ, O’Flaherty K, et al. Host
immunity to Plasmodium falciparum and the assessment of emerging
artemisinin resistance in a multinational cohort. Proceedings of the National
Academy of Sciences. 2017;.
Beshir KB, Hallett RL, Eziefula AC, Bailey R, Watson J, Wright SG, et al. Measuring the
efficacy of anti-malarial drugs in vivo: quantitative PCR measurement of
parasite clearance. Malaria journal [Internet]. 2010;9(1)312 Available from:
http://www.malariajournal.com/content/9/1/312.
Beshir KB, Sutherland CJ, Sawa P, Drakeley CJ, Okell L, Mweresa CK, et al. Residual
Plasmodium falciparum parasitemia in Kenyan children after artemisinin-
combination therapy is associated with increased transmission to mosquitoes
and parasite recurrence. The Journal of infectious diseases [Internet]. 2013;208
(12)2017–24 [cited 2016 Nov 1] Available from: https://www.ncbi.nlm.nih.gov/
pmc/articles/PMC3836468/pdf/jit431.pdf.
Borrmann S, Sasi P, Mwai L, Bashraheil M, Abdallah A, Muriithi S, et al. Declining
responsiveness of Plasmodium falciparum infections to artemisinin-based
combination treatments on the Kenyan coast. PLoSOne [Internet]. 2011;6:
e26005 [cited 2017 Jun 14] (1932-6203 (Electronic)); Available from: www.
plosone.org.
Bouvier P, Rougemont A, Breslow N, Doumbo O, Delley V, Dicko A, et al. Seasonally
and Malaria in a West African Village: Does High Parasite Density Predict Fever
Incidence? [Internet]. Vol. 145. American Journal of Epidemiology 1997;
Available from: https://pdfs.semanticscholar.org/ee94/8165bf089800a33ebfa-
be482888ca82f869e.pdf.
Cheeseman IH, Miller BA, Nair S, Nkhoma S, Tan A, Tan JC, et al. A major genome
region underlying artemisinin resistance in malaria. Science. 2012;336:79–82
(1095-9203 (Electronic)).
Davis TM, Karunajeewa HA, Ilett KF. Artemisinin-based combination therapies for
uncomplicated malaria. MedJAust. 2005;182:181–5 (0025-729X (Print)).
Djimde A, Doumbo OK, Cortese JF, Kayentao K, Doumbo S, Diourte Y, et al. A
molecular marker for chloroquine-resistant falciparum malaria. NEnglJMed.
2001;344:257–63 (0028-4793 (Print)):.
Djimde AA, Doumbo OK, Traore O, Guindo AB, Kayentao K, Diourte Y, et al. Clearance
of drug-resistant parasites as a model for protective immunity in Plasmodium
falciparum malaria. Am J Trop Med Hyg. 2003;69:558–63 (0002-9637 (Print)):.
Djimdé AA, Fofana B, Sagara I, Sidibe B, Toure S, Dembele D, et al. Efficacy, safety, and
selection of molecular markers of drug resistance by two ACTs in Mali. Am J Trop
Med Hyg [Internet]. 2008;78:455–61 [cited 2017 Jun 14] (0002-9637 (Print));
Available from: http://www.ncbi.nlm.nih.gov/pubmed/18337343.
Dolo A, Maïga B, Dara V, Tapily A, Tolo Y, Arama C, et al. Place du paludisme dans les
syndromes fébriles dans deux groupes ethniques vivant en sympatrie au Mali
de 1998 à 2008. Bulletin de la Société de pathologie exotique [Internet].
2012;105(5)377–83 [cited 2020 Mar 21];Available from: http://www.ncbi.nlm.
nih.gov/pubmed/22932999.
Dondorp AM, Nosten F, Yi P, Das D, Phyo AP, Tarning J, et al. Artemisinin resistance in
Plasmodium falciparum malaria. NEnglJMed [Internet]. 2009;361:455–67
[cited 2016 Oct 31];(1533-4406 (Electronic)); Available from: http://www.
nejm.org/doi/pdf/10.1056/NEJMoa0808859.
Flegg JA, Guerin PJ, Nosten F, Ashley EA, Phyo AP, Dondorp AM, et al. Optimal
sampling designs for estimation of Plasmodium falciparum clearance rates in
patients treated with artemisinin derivatives. MalarJ. 2013;12:411 (1475-2875
(Electronic)).
A. Kone et al. / International Journal of Infectious Diseases 95 (2020) 399–405 405Imwong M, Suwannasin K, Kunasol C, Sutawong K, Mayxay M, Rekol H, et al. The
spread of artemisinin-resistant Plasmodium falciparum in the Greater Mekong
subregion: a molecular epidemiology observational study. The Lancet Infectious
Diseases [Internet]. 2017;17(5)491–7 [cited 2018 Feb 16]; Available from:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5406483/pdf/main.pdf.
Kamau E, Campino S, Amenga-Etego L, Drury E, Ishengoma D, Johnson K, et al. K13-
Propeller Polymorphisms in Plasmodium falciparum Parasites From Sub-
Saharan Africa. [cited 2017 May 9]; Available from: https://www.ncbi.nlm.nih.
gov/pmc/articles/PMC4827505/pdf/jiu608.pdf.
Kayentao K, Maiga H, Newman RD, McMorrow ML, Hoppe A, Yattara O, et al.
Artemisinin-based combinations versus amodiaquine plus sulphadoxine-
pyrimethamine for the treatment of uncomplicated malaria in Faladje, Mali.
MalarJ [Internet]. 2009;8:5 [cited 2019 May 1]; (1475-2875 (Electronic));
Available from: http://www.malariajournal.com/content/8/1/5.
Kheang ST, Sovannaroth S, Ek S, Chy S, Chhun P, Mao S, et al. Erratum: Correction to:
Prevalence of K13 mutation and Day-3 positive parasitaemia in artemisinin-
resistant malaria endemic area of Cambodia: a cross-sectional study (Malaria
journal (2017) 16 1 (372)) [Internet]. Vol. 16, Malaria journal. 2017 [cited 2019
Jan 10]. p. 435. Available from: https://www-ncbi-nlm-nih-gov.ezproxy.
nihlibrary.nih.gov/pmc/articles/PMC5598042/pdf/12936_2017_Article_2024.
pdf.
Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time
quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001;25:402–8
(1046-2023 (Print)).
Lopera-Mesa TM, Doumbia S, Chiang S, Zeituni AE, Konate DS, Doumbouya M, et al.
Plasmodium falciparum clearance rates in response to artesunate in Malian
children with malaria: Effect of acquired immunity. Journal of Infectious
Diseases. 2013;.
Madamet M, Kounta MB, Wade KA, Lo G, Diawara S, Fall M, et al. Absence of
association between polymorphisms in the K13 gene and the presence of
Plasmodium falciparum parasites at day 3 after treatment with artemisinin
derivatives in Senegal. International Journal of Antimicrobial Agents [Internet].
2017;49(6)754–6 [cited 2017 Jul 3]; Available from: http://linkinghub.elsevier.
com/retrieve/pii/S0924857917301309.
Maiga AW, Fofana B, Sagara I, Dembele D, Dara A, Traore B, et al. No Evidence of
Delayed Parasite Clearance after Oral Artesunate Treatment of Uncomplicated
Falciparum Malaria in Mali. Am J Trop Med Hyg [Internet]. 2012;87(1)23–8
[cited 2017 Jun 14]; Available from: https://www.ncbi.nlm.nih.gov/pmc/
articles/PMC3391052/pdf/tropmed-87-23.pdf.
Ménard D, Khim N, Beghain J, Adegnika AA, Shafiul-Alam M, Amodu O, et al. A
Worldwide Map of Plasmodium falciparum K13-Propeller Polymorphisms. New
England Journal of Medicine [Internet]. 2016a;374(25)2453–64 [cited 2016 Nov
1]; Available from: http://www.nejm.org/doi/10.1056/NEJMoa1513137.
Ménard D, Khim N, Beghain J, Adegnika AA, Shafiul-Alam M, Amodu O, No Title
2016b;374(25) [cited 2016 Nov 1]; Available from: http://www.ncbi.nlm.nih.
gov/pubmed/27332904.
Miotto O, Amato R, Ashley EA, MacInnis B, Almagro-Garcia J, Amaratunga C, et al.
Genetic architecture of artemisinin-resistant Plasmodium falciparum. Nature
genetics [Internet]. 2015;47(3)226–34 [cited 2019 Nov 22]; Available from:
http://www.ncbi.nlm.nih.gov/pubmed/25599401.
Modiano D, Petrarca V, Sirima BS, Luoni G, Nebie I, Diallo DA, et al. Different
response to Plasmodium falciparum in west African sympatric ethnic groups:
possible implications for malaria control strategies. Parassitologia [Internet].
1999;41(1–3)193–7 [cited 2020 Mar 21]; Available from: http://www.ncbi.nlm.
nih.gov/pubmed/10697855.
Mugittu K, Adjuik M, Snounou G, Ntoumi F, Taylor W, Mshinda H, et al. Molecular
genotyping to distinguish between recrudescents and new infections in
treatment trials of Plasmodium falciparum malaria conducted in Sub-Saharan
Africa: adjustment of parasitological outcomes and assessment of genotyping
effectiveness. Trop Med IntHealth. 2006;11:1350–9 (1360-2276 (Print)).
Mukherjee A, Bopp S, Magistrado P, Wong W, Daniels R, Demas A, et al. Artemisinin
resistance without pfkelch13 mutations in Plasmodium falciparum isolates
from Cambodia. Malaria journal [Internet]. 2017;16(1)195 [cited 2017 Jul 3];
Available from: http://www.ncbi.nlm.nih.gov/pubmed/28494763.
Muwanguzi J, Henriques G, Sawa P, Bousema T, Sutherland CJ, Beshir KB. Lack of K13
mutations in Plasmodium falciparum persisting after artemisinin combination
therapy treatment of Kenyan children. 2016;15:36 [cited 2016 Nov 1]; Available
from: http://www.malariajournal.com/content/15/1/36.
Navaratnam V, Mansor SM, Sit NW, Grace J, Li Q, Olliaro P. Pharmacokinetics of
artemisinin-type compounds. ClinPharmacokinet. 2000;39:255–70 (0312-
5963 (Print)).
Neher RA. MalariaGEN Plasmodium falciparum Community Project. Genomic
epidemiology of artemisinin resistant malaria MalariaGEN Plasmodium
falciparum Community Project*. 2016 [cited 2017 Jun 14]; Available from:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4786412/pdf/elife-08714.pdf.
Noedl H, Se Y, Schaecher K, Smith BL, Socheat D, Fukuda MM. Evidence of
artemisinin-resistant malaria in western Cambodia. NEnglJMed. 2008;
359:2619–20 (1533-4406 (Electronic)).
Ocan M, Akena D, Nsobya S, Kamya MR, Senono R, Kinengyere AA, et al. K13-
propeller gene polymorphisms in Plasmodium falciparum parasite population:
a systematic review protocol of burden and associated factors. Systematic
reviews [Internet]. 2018;7(1)199 [cited 2019 Jan 10]; Available from: https://doi.
org/10.1186/s13643-018-0866-7.
Organization WH. World malaria report 2018. World Health Organization; 2018.Ouattara A, Kone A, Adams M, Fofana B, Maiga AW, Hampton S, et al. Polymorphisms
in the K13-propeller gene in artemisinin-susceptible Plasmodium falciparum
parasites from Bougoula-Hameau and Bandiagara, Mali. American Journal of
Tropical Medicine and Hygiene 2015;92(6):1202–6.
Phyo AP, Nkhoma S, Stepniewska K, Ashley EA, Nair S, McGready R, et al. Emergence
of artemisinin-resistant malaria on the western border of Thailand: a
longitudinal study. Lancet. 2012;379:1960–6 (1474-547X (Electronic)).
Rogier E, Moss DM, Chard AN, Trinies V, Doumbia S, Freeman MC, et al. Evaluation of
Immunoglobulin G Responses to Plasmodium falciparum and Plasmodium
vivax in Malian School Children Using Multiplex Bead Assay. The American
journal of tropical medicine and hygiene [Internet]. 2017;96(2)312–8 [cited
2020 Mar 20]; Available from: http://www.ncbi.nlm.nih.gov/pubmed/
27895279.
Sagara I, Beavogui AH, Zongo I, Soulama I, Borghini-Fuhrer I, Fofana B, et al. Safety
and efficacy of re-treatments with pyronaridine-artesunate in African patients
with malaria: a substudy of the WANECAM randomised trial. The Lancet
Infectious diseases [Internet]. 2016;16(2)189–98 [cited 2020 Mar 18]; Available
from: http://www.ncbi.nlm.nih.gov/pubmed/26601738.
Sangho H, Diawara A, Diallo M, Sow S, Sango HA, Sacko M, et al. [Assessment of
chloroquine resistance two years after stopping chemoprophylaxis in 0 to 9-
year-old children living in a malaria-endemic village of Mali]. Medecine
tropicale: revue du Corps de sante colonial [Internet]. 2004;64(5)506–10 [cited
2019 Jul 10]; Available from: http://www.ncbi.nlm.nih.gov/pubmed/15771023.
Saralamba S, Pan-Ngum W, Maude RJ, Lee SJ, Tarning J, Lindegardh N, et al. Intrahost
modeling of artemisinin resistance in Plasmodium falciparum. ProcNatlAcadS-
ciUSA [Internet] 2011;108:397–402 [cited 2019 Mar 28]; (1091-6490 (Electron-
ic)); Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3017155/
pdf/pnas.201006113.pdf.
Von Seidlein L, Drakeley C, Greenwood B, Walraven G, Targett G. RISK FACTORS FOR
GAMETOCYTE CARRIAGE IN GAMBIAN CHILDREN. Am J Trop Med Hyg
[Internet]. 2001;65(5)523–7 [cited 2017 Jun 14]; Available from: http://www.
ajtmh.org/docserver/fulltext/14761645/65/5/11716108.pdf?expire-
s=1497457839&id=id&accname=guest&checksum=A0DB6923E0C474BC62A-
CE5B2D8D73EE4.
Silachamroon U, Phumratanaprapin W, Krudsood S, Treeprasertsuk S, Budsaratid V,
Pornpininworakij K, et al. Frequency of early rising parasitemia in falciparum
malaria treated with artemisinin derivatives. Southeast Asian Journal of
Tropical Medicine and Public Health [Internet]. 2001;32(1)50–6 [cited 2018 Oct
1]; Available from: http://www.ncbi.nlm.nih.gov/pubmed/11485095.
Snounou G, Beck HP. The use of PCR genotyping in the assessment of recrudescence
or reinfection after antimalarial drug treatment. ParasitolToday. 1998;14:462–7
(0169-4758 (Print)).
Stepniewska K, Ashley E, Lee SJ, Anstey N, Barnes KI, Binh TQ, et al. In vivo
parasitological measures of artemisinin susceptibility. J InfectDis.
2010a;201:570–9 (1537-6613 (Electronic)).
Stepniewska K, Ashley E, Lee SJ, Anstey N, Barnes KI, Binh TQ, et al. In Vivo
Parasitological Measures of Artemisinin Susceptibility. The Journal of
Infectious Diseases [Internet]. 2010b;201(4)570–9 [cited 2018 Jan 5];
Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4291277/
pdf/emss-61705.pdf.
Tacoli C, Gai PP, Bayingana C, Sifft K, Geus D, Ndoli J, et al. Artemisinin resistance-
associated K13 polymorphisms of plasmodium falciparum in Southern Rwanda,
2010-2015. American Journal of Tropical Medicine and Hygiene [Internet].
2016;95(5)1090–3 [cited 2017 Jun 14]; Available from: http://www.ajtmh.org/
docserver/fulltext/14761645/95/5/1090.pdf?expires=1497439399&id=id&acc-
name=trmdmembers&checksum=C7E4D948BB0645DF8433E48296C2CCC0.
Takala-Harrison S, Jacob CG, Arze C, Cummings MP, Silva JC, Dondorp AM, et al.
Independent Emergence of Artemisinin Resistance Mutations Among Plasmo-
dium falciparum in Southeast Asia. JInfectDis. 2014; (1537-6613 (Electronic)).
Taylor SM, Parobek CM, Conrad D, Rosenthal PJ, Tshefu AK, Moormann AM, et al.
Absence of Putative Artemisinin Resistance Mutations Among Plasmodium
falciparum in Sub-Saharan Africa: A Molecular Epidemiologic Study. The
Journal of infectious diseases [Internet]. 2015;211(5)680–8 [cited 2016 Nov 1];
Available from: http://www.ncbi.nlm.nih.gov/pubmed/25180240.
Walsh PS, Metzger DA, Higuchi R. Chelex 100 as a medium for simple extraction of
DNA for PCR-based typing from forensic material. BioTechniques [Internet].
1991;10(4)506–13 [cited 2019 Apr 26]; Available from: http://www.ncbi.nlm.
nih.gov/pubmed/1867860.
White NJ. Malaria parasite clearance [Internet]. Vol. 16. Malaria Journal 2017;88
[cited 2019 Jan 10]. Available from: https://www.ncbi.nlm.nih.gov/pmc/
articles/PMC5324257/pdf/12936_2017_Article_1731.pdf.
WHO. Assessment and monitoring of antimalarial drug efficacy for the treatment of
uncomplicated falciparum malaria _http://www.who.int/malaria/publications/
atoz/whohtmrbm200350/en/_ [Internet]. Vol. WHO/HTM/RB. WHO; 2013 Available
from: http://www.who.int/malaria/publications/atoz/whohtmrbm200350/en/.
WHO. For the treatment of malaria. 2015.
Witkowski, Menard, Amaratunga, Fairhurst. Ring - stage Survival Assays (RSA) to
evaluate the in - vitro and ex - vivo susceptibility of Plasmodium falciparum to
artemisinins. National Institutes of Health Procedure RSAv1.:1-16.
World Health Organization W. World Malaria Report 2018 Isbn 978 92 4 156565 3.
WHO; 2018.
WWARN. Parasite Clearance Estimator Methodology [Internet]. 2010 Available
from: http://www.wwarn.org/sites/default/files/WWARN-Parasite-Clearance-
Estimator-PCE-Methodology.pdf.
